Predicta Biosciences Appoints Dr. Craig L. Tendler as Independent Director
Predicta Biosciences has appointed Dr. Craig L. Tendler, M.D. as an independent director on its Board of Directors. Dr. Tendler has extensive experience in oncology and hematology development programs, focusing on the integration of biomarkers and diagnostics from early development to registration.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, today announced the appointment of Craig L. Tendler, M.D., as an independent director to its Board of Directors. Dr. Tendler brings decades of experience designing and executing oncology and hematology development programs including the integration of biomarkers and diagnostics, from early development and proof of concept through registration. Over the course of